Infliximab and Methotrexate in Ankylosing Spondylitis

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

There is a great individual variability of pharmacokinetic of infliximab in patients treated for ankylosing spondylitis (AS). Moreover, some patients have a treatment with methotrexate (MTX), others have not.

Thus, the aim of this study is to assess the effect of MTX on the pharmacokinetic properties of infliximab in 30 patients treated for AS, 15 with MTX, 15 without.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Tours
• Collaborator: Institut National de la Santé Et de la Recherche Médicale, France
• Treatments: Infliximab; Methotrexate

Criteria

Inclusion Criteria:

• Ankylosing spondylitis

• Needing anti-TNF drugs

Exclusion Criteria:

• Contra-indications to anti-TNF drugs